“We don’t have to do every great deal, but every deal we do has to be great,” says Payal Agrawal Divakaran, partner at .406 Ventures. In this Vanguards of Health Care episode, she joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how .406 backs early-stage startups at the intersection of health care, tech and AI. They dive into the firm’s thesis-driven investing, why care delivery must be reimagined for complex populations and what Epic’s priorities mean for hospital-facing AI startups. Plus, the origins of the firm’s baseball-inspired name and why being mission-driven is non-negotiable for its founders.

Smarter Technologies’ Blueprint for AI-Driven Revenue Cycle Management
52:37

Merck’s GHI Fund and the Push to Rewire Pharma's Future
52:25

Zymeworks on Rethinking Risk, Royalties and R&D
1:03:59